Drugs / TAS3351
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05765734 | May 2023 → Mar 2025 | non-small cell lung carcinoma | Taiho Oncology, Inc. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAS3351 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05765734 ↗ |
| Route | Oral | “TAS3351 administered orally” NCT05765734 ↗ |